MEDIPHARM LABS CORP (LABS.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:LABS - CA58504D1006 - Common Stock
LABS.CA Key Statistics, Chart & Performance
The current stock price of LABS.CA is 0.07 CAD. In the past month the price increased by 7.69%.
LABS.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.95 | 3.83B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.48B | ||
| CRON.CA | CRONOS GROUP INC | 24.87 | 1.43B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.14 | 885.62M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 637.44M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.12 | 634.32M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 584.07M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 593.75M | ||
| TSND.CA | TERRASCEND CORP | N/A | 412.44M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.99 | 392.22M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 331.14M | ||
| HITI.CA | HIGH TIDE INC | N/A | 323.70M |
Related stock screener links
About LABS.CA
Company Profile
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 161 full-time employees. The company went IPO on 2018-02-09. The firm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. The company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The firm cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The firm also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.
Company Info
MEDIPHARM LABS CORP
151 John Street
Barrie ONTARIO L4N 2L1 CA
CEO: Patrick McCutcheon
Employees: 161
Phone: 17057197425
MEDIPHARM LABS CORP / LABS.CA FAQ
What does MEDIPHARM LABS CORP do?
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 161 full-time employees. The company went IPO on 2018-02-09. The firm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. The company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The firm cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The firm also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.
What is the current price of LABS stock?
The current stock price of LABS.CA is 0.07 CAD.
Does MEDIPHARM LABS CORP pay dividends?
LABS.CA does not pay a dividend.
How is the ChartMill rating for MEDIPHARM LABS CORP?
LABS.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the upcoming earnings date for MEDIPHARM LABS CORP?
MEDIPHARM LABS CORP (LABS.CA) will report earnings on 2026-03-30.
LABS.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LABS.CA. When comparing the yearly performance of all stocks, LABS.CA is a bad performer in the overall market: 84.74% of all stocks are doing better.
LABS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LABS.CA. While LABS.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
LABS.CA Financial Highlights
Over the last trailing twelve months LABS.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 22.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.22% | ||
| ROE | -21.2% | ||
| Debt/Equity | 0.01 |
LABS.CA Forecast & Estimates
For the next year, analysts expect an EPS growth of 54.1% and a revenue growth 13.37% for LABS.CA